DNA2 variant analysis supports the nuclease activity as a preferred therapeutic target
Katherine E. Baillie, Sijie Zhang, Veena Mathew, Troy Nations, Balakrishna Koneru, Peter C. Stirling
The paper identifies DNA2 nuclease activity as a preferred therapeutic target in cancer by showing its essential role in DNA repair and fitness, with specific sensitivity in ALT+ tumors.
bioRxiv · Jan 7, 2026 · PreprintCell Biology